ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OVID vs CTMX // EV/EBITDA & P/E VALUATION

Ovid Therapeutics Inc. (NASDAQ) VS. CytomX Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: OVID 6 — CTMX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OVID VS. CTMX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OVID CTMX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -28.50% -20.50% -8.00 CTMX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -7.67% -15.19% +7.52 OVID /fcf-yield <GO>
Operating Margin -60.00% -29.30% -30.70 CTMX /operating-margins <GO>
Net Profit Margin -60.00% -22.80% -37.20 CTMX /net-margins <GO>
Revenue Growth (YoY) 180.00% -44.80% +224.80 OVID /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 11.46 0.20 +11.26 OVID /balance-sheet <GO>
Piotroski F-Score Quality 3/9 1/9 +2.00 OVID /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.1 42.7 +13.41 OVID /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $500.0M $499.0M $973.2K OVID /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OVID REV CTMX REV OVID GROSS % CTMX GROSS % OVID FCF CTMX FCF
FY 2025 $7.3M $76.2M — — -$38.3M -$75.8M
FY 2024 $566.0K $138.1M — — -$56.0M -$86.5M
FY 2023 $392.0K $101.2M — — -$45.8M -$56.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OVID // BETA —
CTMX // BETA —